JAMES A GERAGHTY Insider Trading $GTCB rEVO Biologics, Inc.
FREE EMAIL WATCHDOG
Get free email notifications about insider trading for JAMES A GERAGHTY.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insider Transactions | Monthly Overview
Get the latest insider transactions of JAMES A GERAGHTY. JAMES A GERAGHTY is Director in JUNIPER PHARMACEUTICALS INC ($JNP) and Director in rEVO Biologics, Inc. ($GTCB) and Director in IDERA PHARMACEUTICALS, INC. ($IDRA) and in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in PIERIS PHARMACEUTICALS, INC. ($PIRS) and Director in Voyager Therapeutics, Inc. ($VYGR) and Director in Fulcrum Therapeutics, Inc. ($FULC) and Director in Orchard Therapeutics plc ($ORTX).
JAMES A GERAGHTY in rEVO Biologics, Inc.
Trading Symbol: GTCBIndustry: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
Position of JAMES A GERAGHTY: Director
Holdings: 19,025 shares
Latest Transaction: Jan 05 2010
Last 4 weeks trend: HOLD
Last 3 months trend: HOLD
Latest Insider Trading Transactions of JAMES A GERAGHTY in rEVO Biologics, Inc.
1 Week | 2 Weeks | 1 Month | 3 Months | 6 Months | 1 Year | 2 Years | |
---|---|---|---|---|---|---|---|
No. of Purchases | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Purchases ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
No. of Sales | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Value of Sales ($) | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Sentiment: All, FULC, IDRA, JNP, ORTX, PIRS, GTCB, VYGR
Page: 1
Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
---|---|---|---|---|---|---|---|---|---|---|---|
Jan 05 2010 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.75 | 4,000 | 3,000 | 19,025 | 15 K to 19 K (+26.62 %) |
Sep 28 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.76 | 1,564 | 2,750 | 15,025 | 13.5 K to 15 K (+11.62 %) |
Jun 29 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 2.70 | 1,019 | 2,751 | 13,461 | 12.4 K to 13.5 K (+8.19 %) |
Mar 31 2009 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.33 | 8,333 | 2,750 | 124,426 | 116.1 K to 124.4 K (+7.18 %) |
Dec 29 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.28 | 9,874 | 2,750 | 116,093 | 106.2 K to 116.1 K (+9.30 %) |
Sep 29 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.37 | 7,432 | 2,750 | 106,219 | 98.8 K to 106.2 K (+7.52 %) |
Jun 30 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.40 | 6,841 | 2,750 | 98,787 | 91.9 K to 98.8 K (+7.44 %) |
Apr 01 2008 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.55 | 5,000 | 2,750 | 91,946 | 86.9 K to 91.9 K (+5.75 %) |
Dec 28 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 0.87 | 3,161 | 2,750 | 86,946 | 83.8 K to 86.9 K (+3.77 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,500 | 1,304 | 83,785 | 82.3 K to 83.8 K (+1.82 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,700 | 1,478 | 82,285 | 80.6 K to 82.3 K (+2.11 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 5,400 | 4,697 | 80,585 | 75.2 K to 80.6 K (+7.18 %) |
Dec 17 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 0.87 | 1,400 | 1,216 | 75,185 | 73.8 K to 75.2 K (+1.90 %) |
Oct 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.02 | 2,696 | 2,750 | 73,785 | 71.1 K to 73.8 K (+3.79 %) |
Jul 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.15 | 2,391 | 2,750 | 71,089 | 68.7 K to 71.1 K (+3.48 %) |
Jul 02 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.15 | 2,391 | 2,750 | 71,089 | 68.7 K to 71.1 K (+3.48 %) |
May 25 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.18 | 45,000 | 53,100 | 45,000 | |
Apr 03 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.02 | 1,709 | 1,750 | 68,698 | 67 K to 68.7 K (+2.55 %) |
Jan 03 2007 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 1.11 | 1,577 | 1,750 | 66,989 | 65.4 K to 67 K (+2.41 %) |
Nov 16 2006 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.24 | 2,621 | 3,250 | 65,412 | 62.8 K to 65.4 K (+4.17 %) |
May 16 2005 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.32 | 3,000 | 3,960 | 59,791 | 56.8 K to 59.8 K (+5.28 %) |
Mar 15 2005 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Buy | P | 1.75 | 5,000 | 8,750 | 56,791 | 51.8 K to 56.8 K (+9.65 %) |
May 28 2004 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Option Exercise | A | 1.75 | 22,500 | 39,375 | 22,500 | |
Mar 19 2004 | GTCB | rEVO Biologics, In ... | GERAGHTY JAMES A | Director | Grant | A | 2.14 | 1,000 | 2,141 | 51,791 | 50.8 K to 51.8 K (+1.97 %) |
Page: 1